Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1965 1
1977 1
1979 1
1984 1
1985 1
1986 1
1987 3
1988 2
1989 7
1990 6
1991 6
1992 7
1993 3
1994 6
1995 6
1996 8
1997 14
1998 11
1999 13
2000 11
2001 17
2002 17
2003 16
2004 20
2005 18
2006 20
2007 22
2008 25
2009 25
2010 34
2011 38
2012 23
2013 38
2014 40
2015 59
2016 45
2017 46
2018 53
2019 50
2020 44
2021 44
2022 35
2023 29
2024 28
2025 11
2026 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

836 results

Results by year

Filters applied: . Clear all
Page 1
Author Correction: Alectinib in combination with bevacizumab as first-line treatment in ALK-rearranged non-small cell lung cancer (ALEK-B): a single-arm, phase 2 trial.
Arrieta O, Lara-Mejía L, Rios-Garcia E, Caballé-Perez E, Cabrera-Miranda L, Ramos-Ramírez M, Dávila-Dupont D, Cardona AF, Cruz-Rico G, Remon J, Garcilazo-Reyes A, Rosell R. Arrieta O, et al. Among authors: rosell r. Nat Commun. 2025 Dec 12;16(1):11110. doi: 10.1038/s41467-025-67648-x. Nat Commun. 2025. PMID: 41387445 Free PMC article. No abstract available.
Repurposing risperidone as an anti-angiogenic agent for triple-negative breast cancer: a computational to in ovo investigation.
Jain A, Motatis AKB, Dharmashekar C, Shreevatsa B, Vs S, Srinivas M, Srinivasa SM, P A, Prasad MNN, Rosell R, Codony-Servat J, Rangappa S, Iqbal M, Abass KS, Amachawadi RG, Stupin V, Kollur SP, Shivamallu C, Silina E. Jain A, et al. Among authors: rosell r. Front Oncol. 2025 Oct 28;15:1645905. doi: 10.3389/fonc.2025.1645905. eCollection 2025. Front Oncol. 2025. PMID: 41229499 Free PMC article.
Corrigendum to 'Impact of concurrent genomic alterations on clinical outcomes in patients with ALK-rearranged non-small cell lung cancer' [Journal of Thoracic Oncology, Volume 19 Issue 1 (2024) 119-129].
Lara-Mejía L, Cardona AF, Mas L, Martin C, Samtani S, Corrales L, Cruz-Rico G, Remon J, Galvez-Nino M, Ruiz R, Rios-Garcia E, Tejada F, Lozano-Vazquez N, Rosell R, Arrieta O. Lara-Mejía L, et al. Among authors: rosell r. J Thorac Oncol. 2025 Oct 27:S1556-0864(25)02849-7. doi: 10.1016/j.jtho.2025.10.004. Online ahead of print. J Thorac Oncol. 2025. PMID: 41143757 No abstract available.
Alectinib in combination with bevacizumab as first-line treatment in ALK-rearranged non-small cell lung cancer (ALEK-B): a single-arm, phase 2 trial.
Arrieta O, Lara-Mejía L, Rios-Garcia E, Caballé-Perez E, Cabrera-Miranda L, Ramos-Ramírez M, Dávila-Dupont D, Cardona AF, Cruz-Rico G, Remon J, Garcilazo-Reyes A, Rosell R. Arrieta O, et al. Among authors: rosell r. Nat Commun. 2025 May 16;16(1):4553. doi: 10.1038/s41467-025-59744-9. Nat Commun. 2025. PMID: 40379690 Free PMC article. Clinical Trial.
836 results